Not checkedNot checked for notices yet.
Targeting a therapeutic LIF transgene to muscle via the immune system ameliorates muscular dystrophy
Steven S. Welc, Ivan Flores, Michelle Wehling-Henricks and 4 more
Nature Communications · 2019
doi:10.1038/s41467-019-10614-1 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
A number of therapeutic agents aimed at reducing pathology in Duchenne muscular dystrophy have been developed, but may have off-target effects when delivered systemically. Here, the authors express the therapeutic LIF transgene in leukocytes, and show this results in targeting to inflamed dystrophic muscle and reduced fibrosis by suppressing type 2 immunity.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.